MEZAVANT 1.2 G — DIN 02297558
MESALAZINE : 1.2 G · TAKEDA CANADA INC · TABLET (DELAYED AND EXTENDED RELEASE) · wholesale supply in Canada
Health Canada status: MARKETED
What is MEZAVANT?
MEZAVANT 1.2 G contains MESALAZINE : 1.2 G. It is listed in the Health Canada Drug Product Database under DIN 02297558, held by TAKEDA CANADA INC, supplied as TABLET (DELAYED AND EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 22-Nov-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MEZAVANT used for?
MEZAVANT® (mesalamine delayed- and extended-release tablets) is indicated for: • Induction of remission (clinical and endoscopic) in patients with active, mild to moderate ulcerative colitis. • Maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Mesalazine cost around the world?
Mesalazine is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed |
|---|---|---|---|
| Australia | ex-manufacturer | 8 | 48 |
| Austria | KVP (Kassenverkaufspreis) | 19 | 25 |
| Greece | producer price (ex-factory) | 21 | 21 |
| Saudi Arabia | public | 16 | 21 |
| Czechia | max producer price (ex-factory) | 6 | 17 |
| South Africa | single exit price | 16 | 17 |
| United Arab Emirates | public | 15 | 16 |
| Luxembourg | reimbursement | 16 | 16 |
| Bahrain | retail (max) | 4 | 9 |
| United Kingdom | hospital | 5 | 5 |
| Morocco | PPV (public price) | 1 | 3 |
198 pack listings across 127 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Mesalazine pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Mesalazine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Mesalazine, across 29 DINs, of which 18 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| FERRING INC | 7 | 5 | PENTASA, PENTASA ENEMA 2G/100ML, PENTASA EXTENDED-RELEASE TABLETS 250MG | Sourceable in Canada |
| ABBVIE CORPORATION | 5 | 5 | SALOFALK | Sourceable in Canada |
| AVIR PHARMA INC. | 4 | 4 | MEZERA | Sourceable in Canada |
| TILLOTTS PHARMA AG | 3 | 2 | MESALAMINE, OCTASA | Sourceable in Canada |
| TEVA CANADA LIMITED | 2 | 1 | NTP-5-AMINOSALICYLIC ACID, TEVA-5 ASA | Sourceable in Canada |
| TAKEDA CANADA INC | 1 | 1 | MEZAVANT | Sourceable in Canada |
| ALLERGAN INC | 2 | 0 | ASACOL, ASACOL 800 | No marketed DIN |
| AXCAN PHARMA INC | 2 | 0 | SALOFALK (R) 5-ASA ENTERIC COATED TAB- 250MG, SALOFALK (R) 5-ASA SUPPOSITORIES - 250MG | No marketed DIN |
| GLAXOSMITHKLINE INC | 1 | 0 | MESASAL | No marketed DIN |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 0 | PENDO-5 ASA | No marketed DIN |
| SANIS HEALTH INC | 1 | 0 | 5-ASA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.2 G |
|---|---|
| Dosage form | TABLET (DELAYED AND EXTENDED RELEASE) |
| Route | ORAL |
| Pack configuration (monograph) | MEZAVANT tablets are available as red-brown ellipsoidal film-coated tablets containing 1.2 g of mesalamine, and debossed on one side with S476. MEZAVANT tablets are supplied in opaque high-density polyethylene (HDPE) bottle of 120 tablets with child-resistant closure. |
| Storage | Store at room temperature 15°C to 25°C; excursions permitted to 30°C. Keep out of reach and sight of children. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Mesalazine |
|---|---|
| ATC code | A07EC02 |
| AHFS class | 56:36.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02297558 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2297558 |
| Brand name | MEZAVANT |
| Generic / active ingredient | MESALAZINE : 1.2 G |
| Market authorization holder | TAKEDA CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | A07EC02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A07EC |
| Current status | MARKETED |
| Status date | 22-Nov-2021 |
| Original market date | 2007-07-27 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
MEZAVANT is intended for once daily, oral administration with food. The recommended dose for the induction of remission in patients with mild to moderate ulcerative colitis is two to four 1.2 g tablets to be taken once daily for a total daily dose of 2.4 to 4.8 g. The recommended dose for the maintenance of clinical and endoscopic remission (mucosal healing) is two 1.2 g tablets to be taken once daily for a total daily dose of 2.4 g. As for tablets needing to be swallowed whole, consideration should be given to the ability to swallow the intact tablet. The tablets should be swallowed whole with liquid and should not be crushed or chewed taking care not to break the outer coating. The outer coating is designed to remain intact until at least pH 7, normally in the terminal ileum, to protect the active ingredient, mesalamine, and ensure its availability throughout the colon. If a dose of this medication has been missed, it should be skipped and taken as usual the next day.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
MEZAVANT is contraindicated in: • Patients who are hypersensitive to any salicylates (including mesalamine) or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. • Patients with severe renal impairment (GFR <30 mL/min/1.73 m2) and/or severe hepatic impairment.
Warnings and precautions
Mesalamine products should not be used in patients with urinary tract obstruction, unless the expected benefit outweighs the risks. Extreme caution should be exercised and renal/urinary function should be closely monitored. Mesalamine has been associated with an acute intolerance syndrome that may be difficult to distinguish from a flare of inflammatory bowel disease. Although the exact frequency of occurrence has not been determined, it has occurred in 3% of patients in controlled clinical trials of mesalamine or sulfasalazine. Symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache and rash. If acute intolerance syndrome is suspected, prompt withdrawal is required. In patients with mild to moderate impaired liver function, mesalamine products should be used only if the expected benefits outweigh the risks to the patient. Caution should be exercised. Mesalamine induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported rarely with MEZAVANT and other mesalamine-containing preparations. Caution should be taken in prescribing this medication to patients with conditions predisposing to the development of myocarditis or pericarditis. Mesalamine products should not be used in patients with existing gastric or duodenal ulcer, unless the expected benefit outweighs the risks. Extreme caution should be exercised and adequate care given to those patients. Following mesalamine treatment, serious blood dyscrasias (including myelosuppression) have been reported rarely. The risk is further increased when mesalamine products are used concomitantly with 6-mercaptopurine or azathioprine. If the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat, haematological investigations should be performed. If there is suspicion of blood dyscrasia, mesalamine treatment should be discontinued. There have been reports of hepatic failure and increased liver enzymes in patients with pre-existing liver disease when treated with mesalamine products. Therefore, mesalamine is contraindicated in patients with severe hepatic impairment. In patients with mild to moderate liver function impairment, caution should be exercised and mesalamine products should only be used if the expected benefit clearly outweighs the risks to the patients. Appropriate assessment and monitoring of liver function should be performed. Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered. Reports of renal impairment, including minimal change nephropathy, acute or chronic interstitial nephritis and renal failure have been associated with mesalamine products and pro-drugs of mesalamine. Cases of nephrolithiasis have been reported with the use of mesalazine, including stones with a 100% mesalazine content. Ensure adequate fluid intake during treatment. Patients with chronic lung function impairment, especially asthma, are at risk of hypersensitivity reactions with mesalamine products and should be closely monitored. Photosensitivity: Patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema have reported more severe photosensitivity reactions. Hypersensitivity: Use of mesalazine has been associated with the following serious and life-threatening skin reactions: Drug reaction with eosinophilia and systemic symptoms (DRESS), Severe cutaneous adverse reactions (SCARs), Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN). At the time of prescription, patients should be informed of the signs and symptoms of SJS, TEN and DRESS, and be advised to monitor closely for skin reactions. Discontinue mesalazine at the first signs or symptoms of
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
18 of 29 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEZERA | 500 MG | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | 02524481 |
| MEZERA | 1 G | SUPPOSITORY | AVIR PHARMA INC. | MARKETED | 02474018 |
| MEZERA | 1 G | FOAM | AVIR PHARMA INC. | MARKETED | 02474026 |
| MEZERA | 1 G | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | 02545012 |
| OCTASA | 800 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | 02465752 |
| OCTASA | 1600 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | 02529610 |
| PENTASA | 1 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | 02153521 |
| PENTASA | 1 G | SUPPOSITORY | FERRING INC | MARKETED | 02153564 |
| PENTASA | 4 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | 02153556 |
| PENTASA | 1 G | TABLET (EXTENDED-RELEASE) | FERRING INC | MARKETED | 02399466 |
2 · Same class — other molecules in ATC A07EC
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Mesalazine | 5-ASA · ASACOL · ASACOL 800 · MESALAMINE · +13 more | 29 | 18 | Yes |
| Sulfasalazine | APO SULFASALAZINE TAB 500MG · JAMP SULFASALAZINE · ORB-SULFASALAZINE EC · PMS-SULFASALAZINE 500MG/TAB USP · +10 more | 14 | 5 | Yes |
| Olsalazine | DIPENTUM | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A07E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A07EA | Betamethasone · Budesonide · Hydrocortisone · Tixocortol | 16 | 6 |
| A07EB | Cromoglicic Acid | 1 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MEZAVANT called?
Also recorded in Canada as: mesalamine 400 MG Delayed Release Oral Tablet [Asacol] (US), mesalamine 400 MG Delayed Release Oral Capsule [Delzicol] (US), mesalamine 250 MG Extended Release Oral Capsule [Pentasa] (US), mesalamine 66.7 MG/ML Enema [Rowasa] (US), mesalamine 500 MG Extended Release Oral Capsule [Pentasa] (US), mesalamine 1000 MG Rectal Suppository [Canasa] (US), mesalamine 1200 MG Delayed Release Oral Tablet [Lialda] (US), 24 HR mesalamine 375 MG Extended Release Oral Capsule [Apriso] (US), mesalamine 800 MG Delayed Release Oral Tablet [Asacol] (US), mesalamine 400 MG Delayed Release Oral Capsule (US), mesalamine 500 MG Rectal Suppository (US), mesalamine 66.7 MG/ML Enema (US), mesalamine 250 MG Rectal Suppository (US), mesalamine 1000 MG Rectal Suppository (US), mesalamine 400 MG Delayed Release Oral Tablet (US).
The same molecule, Mesalazine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Salofalk | Latin | Australia, Czechia, Saudi Arabia |
| Pentasa | Latin | Australia, Bahrain, Czechia, Morocco |
| Asacol | Latin | Australia, Bahrain, Czechia, Saudi Arabia |
| Asacol Enema | Latin | Bahrain, Czechia, South Africa |
| ASACOL™ | Latin | United Arab Emirates |
| MESALZ | Latin | Australia |
| Mesasal | Latin | Australia |
| MEZTAS | Latin | Australia |
| PENTASA PROLONG | Latin | Czechia |
| PENTASA SACHET | Latin | Czechia |
| Asacol Suppositories | Latin | South Africa |
| Asacol Tablets | Latin | South Africa |
| COLIZEM | Latin | South Africa |
| Pentasa Klysma | Latin | Austria |
| PENTASA XTEND | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Mesalazine called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Mesalazine, published to help those searches reach this page.
| Language | Mesalazine |
|---|---|
| Arabic العربية | ميسالازين |
| Chinese (Simplified) 简体中文 | 美沙拉嗪 |
| Russian Русский | Месалазин |
| Spanish Español | Mesalazina |
| French Français | Mésalazine |
| Portuguese Português | Mesalazina |
| German Deutsch | Mesalazin |
| Japanese 日本語 | メサラジン |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.